| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new perspective: from internal medicine resident to oncologist
|
Lin, Adam Yuh
|
|
|
19 |
11 |
p. 1433
|
artikel
|
| 2 |
A step towards dignity in life and death
|
Coburn, Cassandra
|
|
|
19 |
11 |
p. e565
|
artikel
|
| 3 |
Avelumab in non-small-cell lung cancer
|
Rosell, Rafael
|
|
|
19 |
11 |
p. 1423-1424
|
artikel
|
| 4 |
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
|
Barlesi, Fabrice
|
|
|
19 |
11 |
p. 1468-1479
|
artikel
|
| 5 |
Bortezomib-based chemotherapy in mantle cell lymphoma
|
Rule, Simon
|
|
|
19 |
11 |
p. 1419-1421
|
artikel
|
| 6 |
Brigatinib versus crizotinib for ALK-positive NSCLC
|
Stirrups, Robert
|
|
|
19 |
11 |
p. e585
|
artikel
|
| 7 |
Combination therapy for first relapse of multiple myeloma
|
Gourd, Elizabeth
|
|
|
19 |
11 |
p. e587
|
artikel
|
| 8 |
Correction to Lancet Oncol 2018; 19: 1192–204
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 9 |
Correction to Lancet Oncol 2018; 19: 1480–92
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 10 |
Correction to Lancet Oncol 2018; 19: 1504–15
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 11 |
Correction to Lancet Oncol 2016; 17: 164–73
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 12 |
Correction to Lancet Oncol 2018; 19: 1289–306
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 13 |
Correction to Lancet Oncol 2018; 19: 1468–79
|
|
|
|
19 |
11 |
p. e581
|
artikel
|
| 14 |
Developing cancer care institutions for the developing world
|
Pereira, Ian
|
|
|
19 |
11 |
p. 1436
|
artikel
|
| 15 |
Developing cancer care institutions for the developing world – Investigator's response
|
Sirohi, Bhawna
|
|
|
19 |
11 |
p. 1436
|
artikel
|
| 16 |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|
Henricks, Linda M
|
|
|
19 |
11 |
p. 1459-1467
|
artikel
|
| 17 |
Duvelisib in haematological malignancies
|
Das, Manjulika
|
|
|
19 |
11 |
p. e586
|
artikel
|
| 18 |
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
|
Robak, Tadeusz
|
|
|
19 |
11 |
p. 1449-1458
|
artikel
|
| 19 |
Genotype-guided fluoropyrimidine dosing: ready for implementation
|
Amstutz, Ursula
|
|
|
19 |
11 |
p. 1421-1422
|
artikel
|
| 20 |
hu3F8 for resistant or recurrent neuroblastoma
|
Burki, Talha Khan
|
|
|
19 |
11 |
p. e583
|
artikel
|
| 21 |
Integrating palliative and oncology care: paediatric considerations
|
Feraco, Angela M
|
|
|
19 |
11 |
p. e572-e573
|
artikel
|
| 22 |
Integrating palliative care into health systems is essential to achieve Universal Health Coverage
|
Knaul, Felicia Marie
|
|
|
19 |
11 |
p. e566-e567
|
artikel
|
| 23 |
Integration of oncology and palliative care: a Lancet Oncology Commission
|
Kaasa, Stein
|
|
|
19 |
11 |
p. e588-e653
|
artikel
|
| 24 |
Integration of oncology and palliative care: less-mentioned issues and a Japanese perspective
|
Uneno, Yu
|
|
|
19 |
11 |
p. e570-e571
|
artikel
|
| 25 |
Lomustine in older patients with acute myeloid leukaemia
|
Gourd, Elizabeth
|
|
|
19 |
11 |
p. e584
|
artikel
|
| 26 |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
Middleton, Mark R
|
|
|
19 |
11 |
p. 1424-1426
|
artikel
|
| 27 |
Lurbinectedin for BRCA-mutated advanced breast cancer
|
Gourd, Elizabeth
|
|
|
19 |
11 |
p. e582
|
artikel
|
| 28 |
Monitoring asparaginase activity
|
Gadelha, Maria Inez Pordeus
|
|
|
19 |
11 |
p. e575
|
artikel
|
| 29 |
Monitoring asparaginase activity
|
Lima, Luís Maurício T R
|
|
|
19 |
11 |
p. e574
|
artikel
|
| 30 |
Monitoring asparaginase activity – Authors' reply
|
Michalowski, Mariana Bohns
|
|
|
19 |
11 |
p. e576
|
artikel
|
| 31 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
|
Hodi, Frank Stephen
|
|
|
19 |
11 |
p. 1480-1492
|
artikel
|
| 32 |
Oncology and palliative care: patients need a seamless service
|
Sykes, Nigel
|
|
|
19 |
11 |
p. e568-e569
|
artikel
|
| 33 |
One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study
|
Zackrisson, Sophia
|
|
|
19 |
11 |
p. 1493-1503
|
artikel
|
| 34 |
Pelvic radiotherapy in prostate cancer: an unresolved question
|
Delouya, Guila
|
|
|
19 |
11 |
p. 1428-1429
|
artikel
|
| 35 |
Personalised approach in follicular lymphoma
|
Luminari, Stefano
|
|
|
19 |
11 |
p. 1431-1432
|
artikel
|
| 36 |
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
|
Trotman, Judith
|
|
|
19 |
11 |
p. 1530-1542
|
artikel
|
| 37 |
Quality of life after breast reconstruction—the BRIOS study
|
Catanuto, Giuseppe
|
|
|
19 |
11 |
p. e578
|
artikel
|
| 38 |
Quality of life after breast reconstruction—the BRIOS study
|
Winters, Zoë E
|
|
|
19 |
11 |
p. e579
|
artikel
|
| 39 |
Quality of life after breast reconstruction—the BRIOS study
|
Potter, Shelley
|
|
|
19 |
11 |
p. e577
|
artikel
|
| 40 |
Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial
|
Velikova, Galina
|
|
|
19 |
11 |
p. 1516-1529
|
artikel
|
| 41 |
Retrorectal tumour
|
Kondo, Takeshi
|
|
|
19 |
11 |
p. e654
|
artikel
|
| 42 |
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
|
Roach, Mack
|
|
|
19 |
11 |
p. 1504-1515
|
artikel
|
| 43 |
Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?
|
Dienstmann, Rodrigo
|
|
|
19 |
11 |
p. 1434-1435
|
artikel
|
| 44 |
The effect of postmastectomy radiotherapy on patient-reported outcomes
|
Rakovitch, Eileen
|
|
|
19 |
11 |
p. 1429-1431
|
artikel
|
| 45 |
The silent victims of the US embargo against Iran
|
Ghalibafian, Mithra
|
|
|
19 |
11 |
p. e580
|
artikel
|
| 46 |
Towards improving accuracy, effectiveness, and efficiency in breast cancer screening
|
Yaffe, Martin J
|
|
|
19 |
11 |
p. 1426-1427
|
artikel
|
| 47 |
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Shitara, Kohei
|
|
|
19 |
11 |
p. 1437-1448
|
artikel
|
| 48 |
Violence, crime, corruption, and cuts in public spending: how to re-establish cancer control in Latin America?
|
The Lancet Oncology,
|
|
|
19 |
11 |
p. 1417
|
artikel
|
| 49 |
9 weeks that matter for patients with gastric cancer
|
Nienhüser, Henrik
|
|
|
19 |
11 |
p. 1418-1419
|
artikel
|
Tijdschrift beschrijving